
Results
2
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
2 companies
argenx
Market Cap: €43.1b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€703.60
7D
0.8%
1Y
16.7%
UCB
Market Cap: €51.3b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€270.20
7D
-3.7%
1Y
48.4%